Expected Launch Date for Apotex's Ruxolitinib Generic
Apotex's generic version of ruxolitinib (referencing Incyte/BMS's Jakafi) faces a Paragraph IV patent challenge. The key U.S. patent (US 8,158,616) expires April 17, 2027, with pediatric exclusivity extending to October 17, 2027. Apotex is among the first ANDA filers eligible for 180-day exclusivity if litigation succeeds, but no FDA tentative approval date is public, and launch is not expected before October 2027 absent a settlement.[1][2]
When Does Jakafi's Patent Protection End?
Core composition patent '616 expires April 17, 2027, plus six months pediatric extension to October 17, 2027. Additional patents cover methods of use (expiring up to 2032) and formulations, but generics target the base compound. Incyte has defended against 15+ ANDAs, with no court losses to date.[2][3]
Which Companies Filed First for Ruxolitinib Generics?
Apotex, Sandoz, and Teva are Paragraph IV first filers, sharing potential 180-day market exclusivity. They sued Incyte in 2021-2022; cases remain pending in Delaware federal court without trial dates set.[1][4]
Has Apotex Gotten FDA Approval Yet?
No final ANDA approval. Apotex submitted its filing around October 2021, but FDA review timelines for complex Paragraph IV drugs like this often exceed 30 months. Tentative approval could come in 2025, but launch hinges on patent rulings.[2]
What Could Delay or Speed Up Launch?
- Settlement risk: Incyte settled with some challengers (e.g., MSN in 2023 for licensed entry post-2027); Apotex talks ongoing but no deal announced.[3]
- Litigation timeline: Hatch-Waxman suits typically take 2-4 years; a win could allow launch at risk, but appeals might push to 2028+.
- Supply/CMC issues: Ruxolitinib requires complex topical and oral formulations; FDA may inspect Apotex facilities before approval.[1][4]
How Does This Compare to Topical Ruxolitinib Generics?
Apotex also challenges Incyte's Opzelura (topical ruxolitinib, patent to 2032+). Separate ANDA, with later expected entry around 2033 unless settled earlier.[2]
[1]: FDA Orange Book for Ruxolitinib
[2]: DrugPatentWatch.com - Jakafi Patents
[3]: Incyte Litigation Tracker
[4]: Apotex ANDA Paragraph IV Certifications